Finally, detectable baseline serum levels of IL-1α were associated with significantly longer PFS in a limited cohort of R/M HNSCC patients treated with cetuximab-based chemotherapy compared to undetectable levels (Fig. 7). The gene discussed is IL1A; the disease is head and neck squamous cell carcinoma.